Botulinum toxin for focal hyperhidrosis of the face

George, S.; Atkinson, Leicester; Farrant, Paul; Shergill, B.

doi:10.1111/bjd.12568

Cited by 13 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, there have been several reports that BTX‐A therapy was effective for HFH 11–13 . In Japan, only a few cases have been reported 14,15 .…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Clinical utility of botulinum toxin type A local injection therapy for head and forehead hyperhidrosis

Ando

Ohshima

Yanagishita

et al. 2022

The Journal of Dermatology

View full text Add to dashboard Cite

Head and forehead hyperhidrosis (HFH) is a disease that causes a large amount of sweating from the head region, and it significantly reduces patients' quality of life. Only a few reports have shown the effectiveness of botulinum toxin type A (BTX‐A) local injection therapy (BTX‐A therapy) for HFH. To clarify the benefits of BTX‐A for HFH, BTX‐A therapy was performed in 15 patients, and its efficacy was evaluated. The amount of sweating was measured by the ventilation capsule method and Minor's iodine‐starch test. Evaluation was also performed using the Hyperhidrosis Disease Severity Scale (HDSS) and the Dermatology Life Quality Index (DLQI). In most cases, a remarkable antiperspirant effect was observed from 2 weeks after the injection, and the effect lasted for approximately 30 weeks. HDSS and DLQI improved along with the decrease in sweating. Two patients (13.3%) complained of transient mild ptosis. There were no serious side‐effects. This study showed that BTX‐A therapy is a safe and effective treatment for HFH.

show abstract

“…To the best of our knowledge, there have been several reports that BTX‐A therapy was effective for HFH 11–13 . In Japan, only a few cases have been reported 14,15 .…”

Section: Discussionmentioning

confidence: 98%

“…[7][8][9][10] To the best of our knowledge, there have been several reports that BTX-A therapy was effective for HFH. [11][12][13] In Japan, only a few cases have been reported. 14,15 Therefore, various factors such as the administration method, dose, period of suppressed sweating, and safety have not been sufficiently investigated.…”

Section: Discussionmentioning

confidence: 99%

Clinical utility of botulinum toxin type A local injection therapy for head and forehead hyperhidrosis

Ando

Ohshima

Yanagishita

et al. 2022

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…In 2013, George SMC et al [21] reported their successful experience with the treatment of craniofacial hyperhidrosis with OnaBTX-A, and they emphasized how important it is for dermatologists to be aware of the application of botulinum toxin and the practical aspects of treatment for managing such patients [16].…”

Section: Discussionmentioning

confidence: 99%

Botulinum Toxin Type A for Treatment of Forehead Hyperhidrosis: Multicenter Clinical Experience and Review from Literature

Campanati

Martina

Gregoriou

et al. 2022

Toxins

View full text Add to dashboard Cite

Among the forms of idiopathic hyperhidrosis, those involving the forehead have the greatest impact on patients’ quality of life, as symptoms are not very controllable and are difficult to mask for patients. Although the local injection therapy with Incobotulinum toxin type A (IncoBTX-A therapy) can be considered a rational treatment, data from the literature describing both efficacy and safety of the treatment over the long term are poor. The aim of this report is to describe the single-center experience of five patients seeking treatment, for forehead hyperhidrosis with IncoBTX-A. To evaluate the benefits, safety profile and duration of anhidrosis, patients were treated following a standardized procedure and then followed until clinical relapse. The amount of sweating was measured by gravimetric testing, the extension of hyperhidrosis area was measured through Minor’s iodine starch test, and response to the treatment was evaluated using the Hyperhidrosis Disease Severity Scale (HDSS) and the Dermatology Life Quality Index (DLQI). In all treated patients, a significant anhidrotic effect was observed 4 weeks after the treatment and lasted for approximately 36 weeks. The reduction in sweat production was associated with significant amelioration of symptoms and quality of life for all treated patients. No serious side effects occurred; one patient complained of a mild transient bilateral ptosis. Although further wider studies are required, our preliminary results seem to encourage the use of IncoBTX-A in forehead hyperhidrosis.

show abstract

“…Although the use of Botulinum toxin A for axillary HH is well established and used worldwide, its use in facial sweating is limited and little literature detailing the dosage, technique and practical considerations are available. 8 Botulinum toxin A blocks the presynaptic release of acetylcholine by destroying a protein complex, SNAP–25, which is necessary for the exocytosis of synaptic vesicles. 15 Boger and colleagues 16 were the first to report Botulinum toxin A use in idiopathic craniofacial HH after its successful use for gustatory HH.…”

Section: Discussionmentioning

confidence: 99%

Intradermal Botulinum Toxin A Injection Versus Topical 2% Glycopyrrolate for the Treatment of Primary Facial Hyperhidrosis: A Pilot Study and Review of Literature

Nofal

Salem

Khashaba

2022

View full text Add to dashboard Cite

BACKGROUNDFacial hyperhidrosis (HH), a common problem with both cosmetic and psychological impact, interferes with quality of life. Wide range of treatment options is available for HH. Finding the most effective and yet a safe, tolerable option is the main target.OBJECTIVETo evaluate and compare clinical efficacy, safety, and tolerability of topical 2% glycopyrrolate versus intradermal Botulinum toxin A injection in facial HH treatment.MATERIALS AND METHODSTwenty-four patients with primary facial HH were randomly divided into 2 equal groups: Group A included patients treated by intradermal Botulinum toxin A injection and Group B included patients treated by topical glycopyrrolate gel 2%. Starch iodine test was performed before and after treatment to assess response, along with Hyperhidrosis Disease Severity Scale, Dermatology Life Quality Index (DLQI), and patient satisfaction.RESULTSBoth modalities showed complete response in 75% of cases with a longer duration of action in botulinum toxin group up to 6 months. Side effects were minor and temporary. Both Hyperhidrosis Disease Severity Scale and DLQI showed statistically significant improvement after treatment.CONCLUSIONTopical glycopyrrolate 2% showed comparable results to Botulinum toxin A in facial HH treatment with faster onset but shorter duration of action.

show abstract

Botulinum toxin for focal hyperhidrosis of the face

Cited by 13 publications

References 5 publications

Clinical utility of botulinum toxin type A local injection therapy for head and forehead hyperhidrosis

Clinical utility of botulinum toxin type A local injection therapy for head and forehead hyperhidrosis

Botulinum Toxin Type A for Treatment of Forehead Hyperhidrosis: Multicenter Clinical Experience and Review from Literature

Intradermal Botulinum Toxin A Injection Versus Topical 2% Glycopyrrolate for the Treatment of Primary Facial Hyperhidrosis: A Pilot Study and Review of Literature

Contact Info

Product

Resources

About